Belapectin

DB15125InvestigationalSmall molecule

Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).

Mechanism: Pharmacologically active on Galectin-3
Curator reviewed
Code names: GR-MD-02

Resolves to

Compound

UNIIK7ODU55HT6CAS1980787-47-0

Targets

P17931LGALS3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Belapectin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account